# Ilika Goliath technical programme made giant steps forwards during the year

- Link: https://www.directorstalkinterviews.com/ilika-goliath-technical-programme-made-giant-steps-forwards-during-the-year/4121045622
- Published: 2022-01-20T07:07:27+00:00
- Author: Giles

**[Ilika plc](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l)**(
[LON:IKA](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l)), a pioneer
in solid-state battery technology, announced today its unaudited half-year report
for the six months ended 31 October 2021.

**Operating Highlights**

Ilika has continued to develop and commercialise its thin-film Stereax^(Ò)^( )miniature
solid-state batteries for powering medical devices and industrial wireless sensors(
IIoT) in hostile environments, as well as progressing its development of large-format
Goliath cells for electric vehicles (EV) and cordless appliances.

·    Secured lease of a 1,600m^(2) property for Stereax manufacturing scale-up

·    Completed the design, installation and commissioning of the 340 m^(2) Stereax
clean room facility

·    Completed installation of Stereax manufacturing line on time and on budget

·    Commenced Stereax manufacturing process qualification

·    Continued to engage with portfolio of Stereax customers from IIoT and medical
device sector

·    Completed Goliath development collaborations with Faraday Battery Challenge
partners including Honda, JLR and McLaren

·    Continued technical progress with the Goliath development programme, including
increased cycle count, reduced operating temperature and increased energy density

·    Commenced Goliath scale up manufacturing design collaboration with Comau, funded
by the Advanced Propulsion Centre

·    Appointed senior additions to management team with Brenadan McCarthy as Goliath
Operations Director and Robin Bell as VP Product Development. 

**Financial Summary**

·    In July 2021, raised c.£25m through a combination of an equity placing, a retail
offer and an open offer

·    Total revenue for the period £0.2m (H1 2021: £1.3m)

Ø _Recognition of the initial allocation of Faraday Battery Challenge grant funding
was completed at the start of the period, resulting in revenue recognition for the
period of £0.2m_

Ø _The environment for grant funding has become tighter but we expect around £0.2m
in H2_

·    Loss per share 2p (H1 2021: 1p)

·    EBITDA loss £2.7m (H1 2021: £1.0m)

Ø _The EBITDA loss was due to the reduction in revenue recognition and the increase
in operational costs associated with the commissioning of the Stereax manufacturing
facility and an intensification of the Goliath development programme_

·    Cash balance at period end £27.7m (H1 2021: £12.4m).

Ø _Cash and cash equivalents at the period end were £27.7m following the placing,
retail offer and open offer in July raising a net £23.7m_

**Post Period End**

·    Officially opened its Stereax Solid-State battery manufacturing facility in
Chandlers Ford to manufacture micro batteries

> **Commenting on the results Graeme Purdy, CEO of Ilika, said:** “Our Stereax manufacturing
> facility has been implemented on time and on budget, despite significant supply
> chain disruption. I’d like to thank our employees, partners and shareholders for
> their support in making this happen. At the same time, our Goliath technical programme
> has made giant steps forwards particularly in operating temperature and cycle 
> life, the equity placing completed in July 2021 will allow us to continue to progress
> towards manufacturing readiness.”

**Joint Chairman’s and CEO’s Statement**

Review of Period

**Principal Activities**

Ilika has continued to pursue its strategy of developing and commercialising its
cutting-edge solid-state batteries. The Company’s mission is to rapidly develop 
leading-edge IP, manufacture and sell solid-state batteries for markets that cannot
be addressed with conventional batteries due to their safety, charge rates, energy
density and life limits. We will achieve this using ceramic-based lithium-ion technology
that is inherently safe in manufacture and usage, which differentiates our products
from existing batteries.

Throughout the year to date, including during the lockdown periods, the Company’s
facilities have remained open. Through the implementation of risk assessments, enhanced
cleaning and hygiene procedures and social distancing, we have maintained a safe
working environment.

**Introduction to Stereax® solid-state battery technology**

Ilika has been working with solid-state battery technology since 2008 and has developed
a type of lithium-ion battery, which, instead of using liquid or polymer electrolyte,
uses a ceramic ion conductor. Ilika’s solid-state batteries have a number of benefits
over traditional lithium-ion batteries, including the following:

·    Non-flammable, which eliminates the need for containment packaging

·    6 x faster charging

·    2x increased energy density, making them half the volume and weight for a given
electrical charge

·    10x longer storage without loss of charge

Ilika has developed a roadmap and family of battery products, ranging from miniature
solid-state devices designed for powering wireless sensor applications and medical
devices to large format cells for automotive power.

**Miniature Stereax batteries**

Ilika’s miniature Stereax cells are differentiated from other solid-state technology
through its choice of materials and its use of an efficient, low temperature evaporation
process that is capable of higher manufacturing rates than other existing solid-
state routes. This results in the following benefits relative to previous solid-
state battery designs:

·    Lower cost of manufacture through avoiding use of expensive sputtering targets

·    Long cycle life through use of a silicon anode

·    Less encapsulation required

·    High temperature resilience

The unique benefits of Stereax batteries make them particularly useful for medical
implants and industrial applications. Miniature Stereax batteries can enable medical
devices in a way that is currently not possible with conventional lithium-ion batteries.
Their compact, high energy density, high power characteristics make them useful 
for a range of medical implant applications covering blood pressure monitoring to
neuro-stimulation. Industrial automation, or Industrial Internet of Things (IIoT)
as it is sometimes referred to, requires low maintenance batteries with a long lifetime,
sometimes in situations that require them to operate at elevated temperatures above
those for which standard lithium-ion batteries are rated (typically 60 degC).

**Stereax® Manufacturing Scale-up and Commercialisation**

In 2020, Ilika had raised funds to support the transfer of Stereax to a manufacturing
facility. Having assessed various manufacturing options, the Company concluded that
the most efficient and cost-effective solution was to establish its own manufacturing
operation. Long lead equipment items were ordered, the lease on a suitable property
was secured and a contract was awarded for the design, installation and commissioning
of a clean room facility. In September 2021, Ilika announced that it had completed
the installation of the clean room and principal equipment. The total area of the
leased property is 1,600 m^(2), in which a 340m^(2) clean room has been installed.
In December 2021, Ilika announced the official opening of the facility by the Rt
Hon Steve Brine MP and Rt Hon Lord Willetts, former Minister of State for Universities
and Science. The official opening was followed up by a Capital Markets Day in which
investors were invited to visit the facility. In line with previous guidance, process
qualification continued through to the end of December 2021 and product qualification
will start in Q1 2022.

The Company has continued to engage with its portfolio of customers from the IIoT
and medical device sectors. The tolerance of Stereax cells of high temperatures 
makes them attractive for powering industrial sensors, while the benefits of Stereax
batteries for medical devices, including miniaturised footprint, biocompatibility,
zero risk of leakage and a long lifespan, underpin their design for applications
including neurostimulation, orthopaedics, ophthalmic sensors and monitoring of heart
rhythm and blood pressure. Commercial sales are expected to start in FY 2023 following
product qualification. Product sales will be ramped up to match demand from a portfolio
of customer new product development (NPD) programmes, with an initial focus on miniature
medical devices.

**Large Format Goliath batteries**

In July 2021, the Company raised £25m through a combination of an equity placing,
a retail offer and an open offer. Ilika outlined that £10m will be used to accelerate
the development of Goliath technology to match and exceed lithium-ion equivalence;
£5m will be used to fund a tenfold increase in capacity of the Goliath pre-pilot
line from 1kWh to 10kWh per week and the remainder will used for working capital
purposes and to support Goliath development until mid-2023. Beyond that, once cell
manufacturing readiness is achieved in 2024, Ilika will transfer production to a
mega-scale facility such as the UK-BIC, with which it has a framework agreement,
before moving to Giga-scale through a JV or licensing.

The Company’s initial development collaborations with its Faraday Battery Challenge
partners including Honda, JLR and McLaren, have been completed. During the course
of those collaborations, Ilika successfully achieved sustained technical progress,
including increased cycle count, reduced operating temperature and increased energy
density.

Work continues with Comau in a programme funded by the APC (Advanced Propulsion 
Centre) to design the Goliath mega-scale facility. Discussions are also progressing
with other supply chain partners to support materials supply and cell manufacturing
scale-up implementation.

**Outlook**

For the remainder of the current financial year, Ilika will continue to qualify 
the process established at its Stereax manufacturing facility and rapidly follow
up with product qualification. Commercial Stereax sales are expected to commence
in the next financial year. The technical maturity of Goliath is expected to continue
to rise as prototype cell performance continuously improves.

Graeme Purdy, CEO

Keith Jackson, Chairman

**Ilika plc**

Share on:
